An open label, multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects with Advanced Solid Tumours or with B-cell Malignancies and in Combination with Temozolomide(TMZ) or with Carboplatin and Paclitaxel in Subjects with Advanced Solid Tumors.

Trial Profile

An open label, multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects with Advanced Solid Tumours or with B-cell Malignancies and in Combination with Temozolomide(TMZ) or with Carboplatin and Paclitaxel in Subjects with Advanced Solid Tumors.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs 2X 121 (Primary) ; Carboplatin; Paclitaxel; Temozolomide
  • Indications B cell lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 05 Jun 2018 Results assessing 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and results of a biomarker analysis, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 16 May 2018 According to an Oncology Venture AB media release, data from this trial will be presented at he American Society for Clinical Oncology (ASCO) for the 2018 ASCO Clinical Meeting.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top